創勝集團 - 全整合型國際化生物制藥公司
創勝集團, 生物藥, 抗體, 藥物研發
13 Sep, 2022
Jifang Gong1 , Ning Li2 , Weijian Guo3, Tianshu Liu4 , Hongli Li5 , Jiayi Li 6 , Zhenzhong Xia7 , Chunhua Qian 7 , Jenny Yao 8 , Jianming Wang 8 , Lijuan Zhang 7 , Chuan Qi 7 , Michael Shi 8 , Xu,Li 8 , Caroline Germa 8 , Xueming Qian 7 , Lin Shen 1 ;
1Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China; 2Henan Cancer Hospital, Zhengzhou, China; 3Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; 4Zhongshan Hospital, Fudan University, Shanghai, China; 5Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 6The First Affiliated Hospital of Xiamen University, Xiamen, China; 7Suzhou Transcenta Therapeutics Co., Ltd; 8Transcenta Therapeutics Inc.
TST001 is a recombinant humanized antibody that can specifically bind to the extracellular structure of Claudin18.2 (CLDN18.2) protein and eliminate cancer cells by antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Pre-clinical studies have shown that TST001 has synergistic effect when used in combination with chemotherapy.
TST001 in combination with CAPOX as the first line treatment of patients with G/GEJ cancer is well tolerated and encouraging anti-tumor activities have been observed. CLDN18.2 expression thresholds and correlation with efficacy are being further assessed.